TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Danish health-record study linked statin use in people with Type 2 diabetes to lower dementia risk, while a Phase 3 study of obicetrapib found lower blood pTau-217 in an ApoE4 subgroup. Neither result shows that cholesterol-lowering drugs prevent or treat Alzheimer’s; a Phase 2b obicetrapib trial is now testing biomarker effects in people without symptoms.
Recent findings have reopened the question of whether cholesterol-lowering drugs could affect Alzheimer’s: a Danish study associated statin use with lower dementia risk among people with Type 2 diabetes, and a Phase 3 study found that obicetrapib lowered a blood Alzheimer’s biomarker in a subgroup carrying the ApoE4 risk gene. Neither finding establishes that the drugs prevent or treat Alzheimer’s, and a new trial is testing whether obicetrapib changes biomarkers in people who have disease hallmarks but no symptoms.
In a study published in Lancet Regional Health – Europe, Shoaib Afzal of Copenhagen University Hospital and colleagues analyzed electronic health records for more than 130,000 people with Type 2 diabetes. The study reported a 15% lower dementia risk over a decade among people who began statins early, and a 10% reduction among those who started later. These are associations from observational data, not proof that statins caused the difference.
The report also describes a NewAmsterdam Pharma study of obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, in people with heart disease or a genetic form of high cholesterol. In a subgroup of 1,727 ApoE4 carriers, the Phase 3 study found lower blood levels of pTau-217, a biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A biomarker change does not show that cognition improved or that disease progression slowed.
NewAmsterdam Pharma has enrolled the first participant in a Phase 2b Alzheimer’s trial. The study is intended to test whether a year of obicetrapib treatment changes Alzheimer’s biomarkers in people with disease hallmarks but no symptoms. Its results will not, by themselves, establish whether treatment prevents symptoms or improves memory and thinking.
What the Findings Could Mean
The findings point to two distinct research questions: whether statins are associated with dementia risk over long periods, and whether a newer cholesterol drug can affect Alzheimer’s-related biology. The distinction matters because a blood biomarker is not the same as a clinical benefit. Patients and families should not interpret these reports as evidence that cholesterol drugs can prevent or treat Alzheimer’s.
Statins are commonly used to reduce cardiovascular risk, including stroke risk. Any decision to start, stop or change cholesterol medication should be based on its established cardiovascular indications and an individual’s circumstances, discussed with a qualified health professional—not on an unproven Alzheimer’s benefit.
As an affiliate, we earn on qualifying purchases.
Why Cholesterol Research Returned
Earlier randomized trials of statins did not show that the medicines treated cognitive decline. A separate randomized trial in healthy adults older than 70 also failed to find a dementia-prevention effect. Those results have made researchers cautious about drawing conclusions from observational studies, where people taking medication may differ in health care access and other behaviors from people who do not.
Researchers are also studying cholesterol processes inside the brain. Blood cholesterol itself does not cross into the brain, according to the report, and statins do not readily reach the brain to alter its cholesterol metabolism. ApoE4 is relevant because it affects cholesterol processing and is associated with increased Alzheimer’s and cardiovascular risk. These biological questions do not establish that changing cholesterol in the blood will change Alzheimer’s disease.
““We could follow people almost up to 20 years.””
— Dr. Shoaib Afzal, Copenhagen University Hospital
Biomarkers Are Not Clinical Outcomes
The Danish study cannot rule out differences between people who took statins and those who did not, including health habits or medical care. The report notes that people using statins may be more medically informed or more likely to follow healthy behaviors. The observed risk reductions therefore do not establish a protective effect.
For obicetrapib, researchers do not yet know whether lower pTau-217 reflects a meaningful change in the brain, whether it affects memory or thinking, or whether it changes the course of Alzheimer’s. The available report gives no evidence that the drug prevents dementia or treats symptoms. The Phase 2b trial is still underway, and its results are pending.
The Obicetrapib Trial’s Next Test
The Phase 2b study will assess whether a year of obicetrapib treatment lowers Alzheimer’s biomarkers in participants who have disease hallmarks but no symptoms. Its findings may help researchers decide whether larger studies of cognitive outcomes are justified. A demonstrated biomarker effect would still need to be followed by evidence about clinical outcomes before the drug could be considered an Alzheimer’s prevention or treatment.
For statins, the key unresolved issue is whether the association in the Danish population would hold up in a long-term randomized trial. Experts cited in the report said such trials could be difficult and costly to conduct. Until stronger evidence is available, the Alzheimer’s implications of both approaches remain uncertain.
Key Questions
Do statins prevent Alzheimer’s?
That has not been established. The Danish study found an association between statin use and lower dementia risk in people with Type 2 diabetes, but observational data cannot show that statins caused the difference. Randomized trials described in the report have not shown a dementia-prevention effect.
Does obicetrapib treat Alzheimer’s?
No clinical benefit has been demonstrated in the findings described. A Phase 3 study found lower blood pTau-217 in an ApoE4 subgroup, but that biomarker result does not show improved cognition or slower disease progression.
What is pTau-217?
pTau-217 is a blood biomarker used to help diagnose Alzheimer’s in people with cognitive impairment. A change in its level is a research finding, not by itself proof of a change in symptoms or disease course.
Should people take cholesterol medicine to prevent dementia?
The report does not support taking cholesterol medication solely to prevent Alzheimer’s. These medicines should be used according to established medical indications; discuss personal treatment decisions with a qualified health professional.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
